pioglitazone has been researched along with Arthritis, Rheumatoid in 5 studies
Pioglitazone: A thiazolidinedione and PPAR GAMMA agonist that is used in the treatment of TYPE 2 DIABETES MELLITUS.
pioglitazone : A member of the class of thiazolidenediones that is 1,3-thiazolidine-2,4-dione substituted by a benzyl group at position 5 which in turn is substituted by a 2-(5-ethylpyridin-2-yl)ethoxy group at position 4 of the phenyl ring. It exhibits hypoglycemic activity.
Arthritis, Rheumatoid: A chronic systemic disease, primarily of the joints, marked by inflammatory changes in the synovial membranes and articular structures, widespread fibrinoid degeneration of the collagen fibers in mesenchymal tissues, and by atrophy and rarefaction of bony structures. Etiology is unknown, but autoimmune mechanisms have been implicated.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Addition of pioglitazone to RA therapy improves insulin resistance and modestly reduces RA disease activity measured by DAS28-CRP and two of its components, including patient-reported global health and CRP, but not DAS28-ESR or ESR." | 5.17 | Peroxisome proliferator-activated receptor γ agonist effect on rheumatoid arthritis: a randomized controlled trial. ( Bian, A; Cunningham, A; Oeser, AM; Ormseth, MJ; Shintani, A; Solus, J; Stein, CM; Tanner, S, 2013) |
| "Pioglitazone treatment resulted in a change in augmentation index of -4." | 2.79 | Reversing vascular dysfunction in rheumatoid arthritis: improved augmentation index but not endothelial function with peroxisome proliferator-activated receptor γ agonist therapy. ( Bian, A; Cunningham, A; Oeser, AM; Ormseth, MJ; Shintani, A; Solus, J; Stein, CM; Tanner, SB, 2014) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (60.00) | 24.3611 |
| 2020's | 2 (40.00) | 2.80 |
| Authors | Studies |
|---|---|
| Li, XF | 1 |
| Yin, SQ | 1 |
| Li, H | 1 |
| Yang, YL | 1 |
| Chen, X | 1 |
| Song, B | 1 |
| Wu, S | 1 |
| Wu, YY | 1 |
| Wang, H | 1 |
| Li, J | 1 |
| Turosz, N | 1 |
| Chęcińska, K | 1 |
| Chęciński, M | 1 |
| Kamińska, M | 1 |
| Nowak, Z | 1 |
| Sikora, M | 1 |
| Chlubek, D | 1 |
| Ormseth, MJ | 2 |
| Oeser, AM | 2 |
| Cunningham, A | 2 |
| Bian, A | 2 |
| Shintani, A | 2 |
| Solus, J | 2 |
| Tanner, S | 1 |
| Stein, CM | 2 |
| Marder, W | 1 |
| Khalatbari, S | 1 |
| Myles, JD | 1 |
| Hench, R | 1 |
| Lustig, S | 1 |
| Yalavarthi, S | 1 |
| Parameswaran, A | 1 |
| Brook, RD | 1 |
| Kaplan, MJ | 1 |
| Tanner, SB | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Inflammation and Insulin Resistance in Rheumatoid Arthritis[NCT00763139] | 34 participants (Actual) | Interventional | 2009-04-30 | Completed | |||
| Peroxisome Proliferator-activated Receptor-gamma Agonists, Rheumatoid Arthritis and Cardiovascular Disease[NCT00554853] | Phase 3 | 143 participants (Actual) | Interventional | 2007-11-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
(NCT00763139)
Timeframe: Measured after 8 weeks of treatment
| Intervention | mg/dl (Mean) |
|---|---|
| Pioglitazone Phase Baseline | 8.1 |
| Pioglitazone Phase After 8 Weeks | 5.02 |
| Placebo Phase Baseline | 7.7 |
| Placebo Phase wk After 8 Weeks | 8.25 |
A measure of disease activity based upon tender joint count of 28 joints, swollen joint count of 28 joints, erythrocyte sedimentation rate, and global disease activity (GH) as reported by participant. Calculation is as follows: DAS28=0.56*sqrt(t28) + 0.28*sqrt(sw28) + 0.70*Ln(ESR) + 0.014*GH (NCT00763139)
Timeframe: Measured after 8 weeks of treatment
| Intervention | units on a scale (Mean) |
|---|---|
| Pioglitazone Phase Baseline | 4.40 |
| Pioglitazone Phase After 8 Weeks | 4.03 |
| Placebo Phase Baseline | 4.57 |
| Placebo Phase wk 8/20 | 4.48 |
sed rate (NCT00763139)
Timeframe: baseline and after 8 weeks on either placebo or pioglitazone
| Intervention | mm/hr (Mean) |
|---|---|
| Pioglitazone Phase Baseline | 18.5 |
| Pioglitazone Phase After 8 Weeks | 17 |
| Placebo Phase Baseline | 19.5 |
| Placebo Phase After 8 Weeks | 18.88 |
Homa is a measure of insulin sensitivity, using glucose measured in mmol/L and insulin measured in milliUnits per liter (mU/L) Calculated using the formula Glucose * Insulin/22/5 (NCT00763139)
Timeframe: Measured after 8 weeks of treatment
| Intervention | units on a scale (Mean) |
|---|---|
| Pioglitazone Phase Baseline | 2.83 |
| Pioglitazone Phase After 8 Weeks | 2.44 |
| Placebo Phase Baseline | 2.38 |
| Placebo Phase wk 8/20 | 3.11 |
This measure represents the percentage change in diameter of brachial artery in response to reactive hyperemia. The data is presented intentionally and only for the results at the conclusion of the study. (NCT00554853)
Timeframe: 8 months
| Intervention | % changes in diameter of artery (Mean) |
|---|---|
| Study Drug (Pioglitazone) Then Placebo | 8.3 |
| Placebo Then Study Drug (Pioglitazone) | 9.43 |
"Quantification of disease activity using validated assessments (disease activity score on 28 joints (DAS28) and and C-reactive protein ( CRP) (Inflammatory marker) as a combined score (DAS-28CRP)).~Mean decrease in DAS-28-CRP score when compared to baseline was measured. The range of DAS-28-CRP is 0-10, with 0 meaning no active disease detected and 10 being the most severe active disease detected by joint count and C-reactive protein levels in blood." (NCT00554853)
Timeframe: 8 mo
| Intervention | mean decrease in DAS28-CRP score (Mean) |
|---|---|
| All Participants While on Placebo | 0.15 |
| All Participants While on Study Drug (Pioglitazone) | .31 |
1 review available for pioglitazone and Arthritis, Rheumatoid
| Article | Year |
|---|---|
A Scoping Review of the Use of Pioglitazone in the Treatment of Temporo-Mandibular Joint Arthritis.
Topics: Animals; Arthritis, Rheumatoid; Inflammation; Pioglitazone; Temporomandibular Joint; Temporomandibul | 2022 |
3 trials available for pioglitazone and Arthritis, Rheumatoid
| Article | Year |
|---|---|
Peroxisome proliferator-activated receptor γ agonist effect on rheumatoid arthritis: a randomized controlled trial.
Topics: Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Blood Sedimentation; C-Reactive Protein; Cross-Ov | 2013 |
The peroxisome proliferator activated receptor-γ pioglitazone improves vascular function and decreases disease activity in patients with rheumatoid arthritis.
Topics: Adult; Aged; Anti-Inflammatory Agents; Antirheumatic Agents; Arthritis, Rheumatoid; Biomarkers; Bloo | 2013 |
Reversing vascular dysfunction in rheumatoid arthritis: improved augmentation index but not endothelial function with peroxisome proliferator-activated receptor γ agonist therapy.
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Cross-Over Studies; Double-Blind Method; E | 2014 |
1 other study available for pioglitazone and Arthritis, Rheumatoid
| Article | Year |
|---|---|
PPAR-γ alleviates the inflammatory response in TNF-α-induced fibroblast-like synoviocytes by binding to p53 in rheumatoid arthritis.
Topics: Animals; Arthritis, Experimental; Arthritis, Rheumatoid; Cell Proliferation; Cells, Cultured; Fibrob | 2023 |